Dasatinib: En ny tyrosinkinaseinhibitor til behandling af kronisk myeloid leukæmi

Ole Weis Bjerrum, Høgh Dufva, Jesper Stentoft, Hans Carl Hasselbalch

    Publikation: Bidrag til tidsskriftArtikelForskningpeer review

    Abstrakt

    Chronic myeloid leukaemia is characterized by an abnormal tyrosin kinase in the cytoplasm of the clonal cells. The enzyme is derived from a fusion gene on the Philadelphia-chromosome, evolved by a translocation between chromosomes 9 and 22. Understanding the biology of the tyrosin kinase led to targeted therapy, inhibiting the ATP-binding site by a small molecule - imatinib (Glivec). A novel 2nd generation tyrosin kinase inhibitor dasatinib (Sprycel) - is now available in cases of insufficient response or intolerance to imatinib.

    Bidragets oversatte titelDasatinib (Sprycel): A novel tyrosine kinase inhibitor for the treatment of chronic myeloid leukaemia
    OriginalsprogDansk
    Sider (fra-til)331-333
    Antal sider3
    TidsskriftUgeskrift for laeger
    Vol/bind170
    Udgave nummer5
    StatusUdgivet - 28 jan. 2008

    Fingeraftryk

    Udforsk hvilke forskningsemner 'Dasatinib: En ny tyrosinkinaseinhibitor til behandling af kronisk myeloid leukæmi' indeholder.

    Citationsformater